Single Cell Technology was incorporated in California in 2008 and moved into the San Jose BioCenter in September. The CEO is Dr. Chun-Nan Chen and the COO is Jim Bowlby.

The mission of Single Cell Technology is to identify, characterize and improve a very large number of high affinity antibodies. We intend to bring these advances to the international marketplace in a sustainable and socially responsible manner.

The company is currently securing its intellectual property by performing wet-lab experiments. We anticipate commercializing our basic services in early 2009.

SCT is discussing the licensing of collagen based antibodies from the Industrial and Technical Research Institute (ITRI) in Taiwan.